WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products, today announced the reporting of positive interim clinical data with trastuzumab-DM1 (T-DM1) for first-line treatment of HER2+ metastatic breast cancer in a press release issued by the European Society for Medical Oncology (ESMO). T-DM1 consists of ImmunoGen’s DM1 cancer cell-killing agent attached to the HER2-targeting antibody, trastuzumab, developed by Genentech, a member of the Roche Group. The compound is in global development by Roche under a collaboration agreement between ImmunoGen and Genentech.
